A provider briefing on Breyna availability in 2026. Shortage timeline, prescribing implications, cost updates, alternatives, and tools for helping patients find stock.
If your patients have been reporting difficulty filling their Breyna (Budesonide/Formoterol Fumarate Dihydrate) prescriptions, you're not alone in hearing it. While Breyna is not currently on the FDA's formal drug shortage list, intermittent availability gaps have persisted since the product's 2023 launch, creating real challenges for patient adherence and clinical management.
This briefing covers the supply timeline, prescribing implications, the current availability and cost landscape, and actionable tools you can use to help your patients maintain access to their ICS/LABA therapy.
Viatris, in partnership with Kindeva Drug Delivery, launched Breyna as the first FDA-approved generic of AstraZeneca's Symbicort. The product was approved via an Abbreviated New Drug Application (ANDA) and is available in two strengths: 80/4.5 mcg and 160/4.5 mcg, each providing 120 actuations per canister.
Symbicort itself had experienced intermittent shortages driven by respiratory illness surges, supply chain disruptions, and manufacturing capacity constraints. As Breyna captured significant market share quickly, demand occasionally outpaced wholesaler allocations. The FDA did not place Symbicort or Breyna on its critical shortage list during this period, but regional availability gaps were widely reported by pharmacists and patients.
By mid-2025, overall supply of Budesonide/Formoterol MDIs had improved as manufacturing scaled and additional generic entrants signaled interest. However, wholesaler allocation policies continued to create patchwork availability, with some pharmacies consistently stocked and others intermittently running out.
Breyna remains off the FDA shortage list. Supply is generally adequate at the national level, but localized availability gaps persist due to allocation limits, regional demand variation, and pharmacy ordering patterns. Providers should anticipate that some patients will continue to experience difficulty at individual pharmacies.
The supply situation has several implications for clinical practice:
Patients who cannot fill their Breyna prescription on time may go days or weeks without their maintenance ICS/LABA therapy, increasing the risk of asthma exacerbations, COPD flare-ups, and emergency department visits. Studies consistently show that even short gaps in controller therapy can lead to clinically significant deterioration.
When Breyna is unavailable, the most straightforward substitution is brand-name Symbicort (identical active ingredients and strengths). If Symbicort is also unavailable or cost-prohibitive, consider:
When switching, refer to the American Lung Association's comparative dosing charts to find equivalent ICS doses across products. For a patient-facing overview, see alternatives to Breyna.
Encourage patients to call their pharmacy before visiting and to request special orders. Advise them to refill 7–10 days before running out. Providing patients with specific product information (NDC numbers, both strengths) can help pharmacists locate stock more efficiently.
Key factors affecting current availability:
Understanding the cost landscape helps when counseling patients:
For a patient-facing cost breakdown, direct patients to saving money on Breyna.
Several tools can help you and your patients navigate availability challenges:
Several trends suggest Breyna availability will continue to improve:
However, individual pharmacy-level gaps may persist for the near term. Building awareness of alternatives and availability tools into your practice workflow will help minimize disruptions to patient care.
Breyna is an effective, more affordable ICS/LABA option for your asthma and COPD patients. While the supply picture has improved meaningfully since launch, localized availability challenges remain. By staying informed about the current landscape, proactively discussing alternatives, and directing patients to tools like Medfinder, you can help ensure your patients maintain consistent access to their respiratory therapy.
For a practical guide to helping patients find Breyna at the pharmacy level, see How to help your patients find Breyna in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
